Rebecca G Same1, Alice J Hsu2, Sara E Cosgrove3, Eili Y Klein4, Joe Amoah1, Adam L Hersh5, Matthew P Kronman6, Pranita D Tamma1. 1. Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA. 3. Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA. 6. Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: Antibiotic-associated adverse events (AEs) in hospitalized children have not been comprehensively characterized. METHODS: We conducted a retrospective observational study of children hospitalized at The Johns Hopkins Hospital receiving ≥24 hours of systemic antibiotics. Consensus regarding antibiotic-associated AE definitions was established by 5 infectious diseases specialists prior to data collection. Two physicians reviewed potential AEs and determined whether they were more likely than not related to antibiotics after comprehensive manual chart review. Inpatient and post-discharge AEs were identified using the Epic Care Everywhere network. AEs evaluated from the initiation of antibiotics until 30 days after antibiotic completion included gastrointestinal, hematologic, hepatobiliary, renal, neurologic, dermatologic, cardiac, myositis, vascular access device-related events, and systemic reactions. Ninety-day AEs included Clostridioides difficile infections, multidrug-resistant organism infections, and clinically significant candidal infections. The impact of AEs was categorized as necessitating additional diagnostic testing, changes in medications, unplanned medical encounters, prolonged or new hospitalizations, or death. RESULTS: Among 400 antibiotic courses, 21% were complicated by at least one AE and 30% occurred post-discharge. Each additional day of antibiotics was associated with a 7% increased odds of an AE. Of courses complicated by an AE, 66% required further intervention. Hematologic, gastrointestinal, and renal AEs were the most common, accounting for 31%, 15%, and 11% of AEs, respectively. AEs complicated 35%, 35%, 19%, and 18% of courses of piperacillin-tazobactam, tobramycin, ceftazidime, and vancomycin, respectively. CONCLUSIONS: More than 1 in 5 courses of antibiotics administered to hospitalized children are complicated by AEs. Clinicians should weigh the risk of harm against expected benefit when prescribing antibiotics.
BACKGROUND: Antibiotic-associated adverse events (AEs) in hospitalized children have not been comprehensively characterized. METHODS: We conducted a retrospective observational study of children hospitalized at The Johns Hopkins Hospital receiving ≥24 hours of systemic antibiotics. Consensus regarding antibiotic-associated AE definitions was established by 5 infectious diseases specialists prior to data collection. Two physicians reviewed potential AEs and determined whether they were more likely than not related to antibiotics after comprehensive manual chart review. Inpatient and post-discharge AEs were identified using the Epic Care Everywhere network. AEs evaluated from the initiation of antibiotics until 30 days after antibiotic completion included gastrointestinal, hematologic, hepatobiliary, renal, neurologic, dermatologic, cardiac, myositis, vascular access device-related events, and systemic reactions. Ninety-day AEs included Clostridioides difficile infections, multidrug-resistant organism infections, and clinically significant candidal infections. The impact of AEs was categorized as necessitating additional diagnostic testing, changes in medications, unplanned medical encounters, prolonged or new hospitalizations, or death. RESULTS: Among 400 antibiotic courses, 21% were complicated by at least one AE and 30% occurred post-discharge. Each additional day of antibiotics was associated with a 7% increased odds of an AE. Of courses complicated by an AE, 66% required further intervention. Hematologic, gastrointestinal, and renal AEs were the most common, accounting for 31%, 15%, and 11% of AEs, respectively. AEs complicated 35%, 35%, 19%, and 18% of courses of piperacillin-tazobactam, tobramycin, ceftazidime, and vancomycin, respectively. CONCLUSIONS: More than 1 in 5 courses of antibiotics administered to hospitalized children are complicated by AEs. Clinicians should weigh the risk of harm against expected benefit when prescribing antibiotics.
Authors: Jeffrey S Gerber; Jason G Newland; Susan E Coffin; Matt Hall; Cary Thurm; Priya A Prasad; Chris Feudtner; Theoklis E Zaoutis Journal: Pediatrics Date: 2010-11-15 Impact factor: 7.124
Authors: Jeffrey S Gerber; Rachael K Ross; Matthew Bryan; A Russell Localio; Julia E Szymczak; Richard Wasserman; Darlene Barkman; Folasade Odeniyi; Kathryn Conaboy; Louis Bell; Theoklis E Zaoutis; Alexander G Fiks Journal: JAMA Date: 2017-12-19 Impact factor: 56.272
Authors: Julia E Szymczak; Brandi M Muller; Nikitha Shankar Shakamuri; Keith W Hamilton; Jeffrey S Gerber; Maryrose Laguio-Vila; Ghinwa K Dumyati; Scott K Fridkin; Alice Y Guh; Sujan C Reddy; Ebbing Lautenbach Journal: Infect Control Hosp Epidemiol Date: 2020-05-29 Impact factor: 3.254
Authors: Leslie M Stach; Erin B Hedican; Joshua C Herigon; Mary Anne Jackson; Jason G Newland Journal: J Pediatric Infect Dis Soc Date: 2012-06-29 Impact factor: 3.164
Authors: Preeti Jaggi; Rana F Hamdy; Brian Lee; Adam L Hersh; Jeffrey S Gerber; Mike Sharland; Cindy Terrill; Jason G Newland Journal: J Pediatric Infect Dis Soc Date: 2020-09-17 Impact factor: 3.164
Authors: Charlotte Z Woods-Hill; Anping Xie; John Lin; Heather A Wolfe; Alex S Plattner; Sara Malone; Kathleen Chiotos; Julia E Szymczak Journal: JAC Antimicrob Resist Date: 2022-01-22
Authors: Emma Whittle; Jennifer A Yonkus; Patricio Jeraldo; Roberto Alva-Ruiz; Heidi Nelson; Michael L Kendrick; Thomas E Grys; Robin Patel; Mark J Truty; Nicholas Chia Journal: mSphere Date: 2022-02-16 Impact factor: 4.389